Clinical utility of cerebrospinal fluid biomarkers in the evaluation of cognitive impairment: a systematic review and meta-analysis

被引:17
|
作者
Hazan, Jemma [1 ]
Wing, Michelle [1 ]
Liu, Kathy Y. [1 ]
Reeves, Suzanne [1 ]
Howard, Robert [1 ]
机构
[1] UCL, Div Psychiat, London, England
来源
关键词
DEMENTIA; ALZHEIMER'S DISEASE; CSF; ALZHEIMERS-DISEASE; CSF BIOMARKERS; DIAGNOSTIC IMPACT; PHOSPHORYLATED TAU; COST-EFFECTIVENESS; DEMENTIA; AMYLOID-BETA(1-42); PERFORMANCE; FRAMEWORK;
D O I
10.1136/jnnp-2022-329530
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background The analytical and clinical validity of cerebrospinal (CSF) biomarkers has been extensively researched in dementia. Further work is needed to assess the ability of these biomarkers to improve diagnosis, management and health outcomes in the clinical setting Objectives To assess the added value and clinical utility of CSF biomarkers in the diagnostic assessment of cognitively impaired patients under evaluation for Alzheimer's disease (AD). Methods Systematic literature searches of Medline, EMBASE, PsycINFO and Web of Science research databases were conducted on 17 December 2022. Data from relevant studies were extracted and independently screened for quality using a tool for bias. Clinical utility was measured by clinicians' changes in diagnosis, diagnostic confidence and patient management (when available), after their examination of patients' CSF biomarkers. Cost-effectiveness was assessed by consideration of additional cost per patient and quality-adjusted life years. Results Searches identified 17 studies comprising 2090 patient participants and 593 clinicians. The meta-analysis revealed that clinicians' use of CSF biomarkers resulted in a pooled percentage change in diagnosis of 25% (95% CI 14 to 37), an increase in diagnostic confidence of 14% (95% CI 9 to 18) and a pooled proportion of patients whose management changed of 31% (95% CI 12 to 50). CSF biomarkers were deemed cost-effective, particularly in memory services, where pre-test AD prevalence is higher compared with a primary care setting. Conclusions CSF biomarkers can be a helpful additional diagnostic tool for clinicians assessing patients with cognitive impairment. In particular, CSF biomarkers consistently improved clinicians' confidence in diagnosing AD and influenced on diagnostic change and patient management. Further research is needed to study the clinical utility of blood-based biomarkers in the clinical setting.
引用
收藏
页码:113 / 120
页数:8
相关论文
共 50 条
  • [41] Potential Biomarkers of Post-stroke Cognitive Impairment in Chinese Population: a Systematic Review and Meta-Analysis
    Jiang, Zhuoya
    Li, Min
    Wang, Kunyu
    Duan, Hanying
    Zhang, Beilin
    Fang, Shaokuan
    MOLECULAR NEUROBIOLOGY, 2025,
  • [42] The diagnostic utility of cerebrospinal fluid alpha-synuclein analysis in dementia with Lewy bodies - A systematic review and meta-analysis
    Lim, Xuxin
    Yeo, Jing Ming
    Green, Alison
    Pal, Suvankar
    PARKINSONISM & RELATED DISORDERS, 2013, 19 (10) : 851 - 858
  • [43] A Systematic Review and Meta-Analysis of Cerebrospinal Fluid Amyloid and Tau Levels Identifies Mild Cognitive Impairment Patients Progressing to Alzheimer's Disease
    Ma, Yunxing
    Brettschneider, Julia
    Collingwood, Joanna F.
    BIOMEDICINES, 2022, 10 (07)
  • [44] The prognostic significance of biomarkers in cerebrospinal fluid following severe traumatic brain injury: a systematic review and meta-analysis
    Hvingelby, Victor Schwartz
    Bjarkam, Carsten Reidies
    Mathiesen, Tiit Illimar
    Poulsen, Frantz Rom
    Botker, Morten Thingemann
    Husted, Andreas
    Korshoej, Anders Rosendal
    NEUROSURGICAL REVIEW, 2022, 45 (04) : 2547 - 2564
  • [45] Cerebrospinal Fluid Biomarkers in Patients With Unipolar Depression Compared With Healthy Control Individuals A Systematic Review and Meta-analysis
    Mousten, Ina Viktoria
    Sorensen, Nina Vindegaard
    Christensen, Rune Haubo B.
    Benros, Michael Eriksen
    JAMA PSYCHIATRY, 2022, 79 (06) : 571 - 581
  • [46] The prognostic significance of biomarkers in cerebrospinal fluid following severe traumatic brain injury: a systematic review and meta-analysis
    Victor Schwartz Hvingelby
    Carsten Reidies Bjarkam
    Tiit Illimar Mathiesen
    Frantz Rom Poulsen
    Morten Thingemann Bøtker
    Andreas Husted
    Anders Rosendal Korshoej
    Neurosurgical Review, 2022, 45 : 2547 - 2564
  • [47] Author Correction: A meta-analysis of the diagnostic utility of biomarkers in cerebrospinal fluid in Parkinson’s disease
    Chunchen Xiang
    Shengri Cong
    Xiaoping Tan
    Shuang Ma
    Yang Liu
    Hailong Wang
    Shuyan Cong
    npj Parkinson's Disease, 9
  • [48] Saffron for mild cognitive impairment and dementia: a systematic review and meta-analysis of randomised clinical trials
    Ayati, Zahra
    Yang, Guoyan
    Ayati, Mohammad Hossein
    Emami, Seyed Ahmad
    Chang, Dennis
    BMC COMPLEMENTARY MEDICINE AND THERAPIES, 2020, 20 (01)
  • [49] Clinical efficacy of Danshen preparation in the treatment of vascular cognitive impairment: A systematic review and meta-analysis
    Li, Yunze
    Yao, Yangjing
    Cao, Xinran
    Yi, Nan
    Chen, Anqi
    Li, Jianjun
    Wu, Minghua
    FRONTIERS IN AGING NEUROSCIENCE, 2023, 14
  • [50] Saffron for mild cognitive impairment and dementia: a systematic review and meta-analysis of randomised clinical trials
    Zahra Ayati
    Guoyan Yang
    Mohammad Hossein Ayati
    Seyed Ahmad Emami
    Dennis Chang
    BMC Complementary Medicine and Therapies, 20